文献速递胸部肿瘤

Izalontamab Brengitecan治疗非经典EGFR突变外可靶向基因组变异NSCLC的Ib期研究

Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.
PubMed 文献 · J Clin Oncol · 2026-03-04

该Ib期研究评估了izalontamab brengitecan(iza-bren)在携带非经典EGFR突变外可靶向基因组变异(GAs)的局部晚期或转移性非小细胞肺癌(NSCLC)患者中的安全性和疗效。共83例患者分四队列,最常见≥3级治疗相关不良事件为血小板减少(51.8%)、贫血(44.6%)和中性粒细胞减少(43.4%)。确认客观缓解率(ORR)39.7%,疾病控制率(DCR)85.9%,中位无进展生存期(PFS)7.0个月(95%CI 5.4-10.5)。

要点

  • iza-bren在经治NSCLC多种GAs中显示抗肿瘤活性,确认ORR 39.7%,DCR 85.9%。
  • EGFR exon20ins/非经典突变队列ORR 69.2%,中位PFS 10.5个月。
  • HER2突变队列ORR 52.9%,中位PFS 7.5个月;≥3级血液学毒性常见。

核心结论

  • iza-bren在非经典EGFR突变外的多种可靶向GAs经治NSCLC中显示令人鼓舞的抗肿瘤活性和可控的安全性。

研究设计与样本

  • Ib期研究,纳入局部晚期或转移性NSCLC且携带预设可靶向GAs、标准治疗进展后且既往化疗不超过一线的患者。
  • iza-bren剂量为2.5 mg/kg,每3周周期第1天和第8天每日一次给药。
  • 共83例患者入组四个队列:EGFR exon20ins/非经典突变(n=14)、HER2突变(n=19)、KRAS/BRAF/MET突变(n=26)、ALK/ROS1/RET/NTRK融合(n=24)。

主要发现

  • 最常见≥3级治疗相关不良事件(TRAEs)为血小板减少(51.8%)、贫血(44.6%)和中性粒细胞减少(43.4%)。
  • 最常见全等级非血液学TRAEs为恶心(49.4%)、乏力(45.8%)、口腔炎(44.6%)和腹泻(38.6%);观察到1例2级间质性肺病。
  • 确认ORR为39.7%,DCR为85.9%;中位PFS为7.0个月(95%CI 5.4-10.5),OS数据未成熟。
  • EGFR exon20ins或其他非经典突变患者ORR为69.2%,中位PFS为10.5个月(95%CI 6.9-未达到);HER2突变队列ORR为52.9%,中位PFS为7.5个月(95%CI 5.4-未达到)。

临床怎么用

  • 对于携带非经典EGFR突变外可靶向GAs的经治NSCLC患者,iza-bren可作为潜在治疗选择,尤其EGFR exon20ins/非经典突变和HER2突变。
  • 治疗期间需密切监测血液学毒性(血小板减少、贫血、中性粒细胞减少)及非血液学毒性(恶心、乏力、口腔炎、腹泻)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of izalontamab brengitecan (iza-bren) in patients with non-small cell lung cancer (NSCLC) harboring actionable genomic alterations (GAs) outside of classical epidermal growth factor receptor (EGFR) mutations. METHODS: Eligible patients had locally advanced or metastatic NSCLC with prespecific actionable GAs, had progressed after standard treatment and received no more than one previous line of chemotherapy. iza-bren was administered at the dose of 2.5 mg/kg once per day on days 1 and 8 of each 3-week cycle. The primary end point was safety. The secondary end points included objective response rate (ORR), disease control rate (DCR), and duration of response. The exploratory end points included progression-free survival (PFS) and overall survival (OS). RESULTS: A total of 83 patients with NSCLC were enrolled in four cohorts: EGFR exon20ins/nonclassical mutations (n = 14), human epidermal growth factor receptor 2 (HER2) mutation (n = 19), KRAS/BRAF/MET mutation (n = 26), and ALK/ROS1/RET/NTRK fusion (n = 24). The most common grade ≥3 treatment-related adverse events (TRAEs) were thrombocytopenia (51.8%), anemia (44.6%), and neutropenia (43.4%). The most frequent nonhematologic TRAEs of all grades were nausea (49.4%), asthenia (45.8%), stomatitis (44.6%), and diarrhea (38.6%). One case of grade 2 interstitial lung disease was observed. The confirmed ORR was 39.7%, and the DCR was 85.9%. The median PFS was 7.0 months (95% CIs, 5.4 to 10.5), while OS data were immature. Patients with EGFR exon20ins or other nonclassical mutations achieved an ORR of 69.2% with a median PFS of 10.5 months (95% CI, 6.9 to not reached); the HER2-mutant cohort had an ORR of 52.9% and a median PFS of 7.5 months (95% CI, 5.4 to not reached). CONCLUSION: iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical EGFR mutations, especially in EGFR exon20ins/nonclassical and HER2 mutations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou H, Zhao H, Hou X, et al. Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study. J Clin Oncol. 2026. PMID: 41779981. doi:10.1200/JCO-25-01929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。